Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway.
Ann MedApr 30, 2026 (epub)
Yanyan Lin, Yaling Wang, Wanjing Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of topical 3% tranexamic acid (TXA) on periorbital wrinkles in 50 women with facial melasma over 12 weeks. TXA significantly reduced wrinkles compared to moisturizer alone, with benefits lasting post-treatment. Additionally, TXA protected human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway.
Key findings
- TXA led to significantly greater reductions in MFWS compared to moisturizer alone at weeks 4, 8, and 12.
- TXA preserved fibroblast viability and reduced SA-β-gal positivity in D-galactose-induced senescence models.
- TXA downregulated pro-inflammatory markers IL-6, IL-8, MMP1, and MMP3.
- TXA's protective effects were diminished by GPR30 antagonism or knockdown.
Why it matters
The findings suggest that tranexamic acid may not only address pigmentary disorders but also offer anti-aging benefits, potentially enhancing treatment options for skin aging in clinical practice.